fosamax actonel
Click on image below to visit fosamax Online Page
Business Editors/Health & Pharmaceutical Writers
MINNEAPOLIS–(BUSINESS WIRE)–Sept. 22, 2003
Merck & Co., Inc. (NYSE:MRK)
FOSAMAX and Evista Demonstrated Similar Upper GI Safety and Overall
Tolerability Profiles in Two Head-to-Head Studies Presented at ASBMR
In one-year head-to-head trials comparing FOSAMAX(R)(alendronate sodium) once-weekly, the most prescribed medicine(1) for osteoporosis treatment, to Evista, FOSAMAX 70 mg provided significantly greater increases in bone mineral density (BMD) at one-year at the lumbar spine and total hip compared to Evista (raloxifene) 60 mg once-daily. Findings from these two studies, one conducted in the U.S. and one internationally, were presented this week at the 25th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).
“These studies are important because they are the first to compare weekly alendronate to raloxifene once daily,” said Risa Kagan, M.D., co-medical director, FORE-Foundation for Osteoporosis Research and Education, Oakland, Calif. and a researcher on the study. “Because these medicines work by different mechanisms, clinical studies like these provide doctors with helpful information on efficacy and tolerability, which helps in making treatment decisions for patients.”
Significantly more women responded to treatment with FOSAMAX than with Evista
Advertisement
In both of these studies, after one year of treatment, postmenopausaColorado fosamax lawyers
Fosamax skin redenning
Side effects of fosamax
Fosamax and jaw rottening disease
Compare actonel evista fosamax
Prednisone lawsuit compensation jaw fosamax deadjaw
Stopping fosamax after cataract surgery